Association of initial hemodialysis vascular access with patient-reported health status and quality of life.
BACKGROUND
Although the arteriovenous fistula (AVF) is the recommended form of vascular access for patients with ESRD, its impact on patient perception of health status, quality of life (QOL), or satisfaction is unknown.


METHODS
This study compared patient-reported health status and QOL scores and vascular access type among a national random sample of 1563 patients at dialysis initiation and day 60 of ESRD during 1996 to 1997. Patients were stratified into five categories: AVF at first dialysis and day 60 of ESRD, arteriovenous graft (AVG) at first dialysis and day 60, central venous catheter (CVC) at first dialysis and AVF at day 60, CVC at first dialysis and AVG at day 60, and CVC at first dialysis and day 60.


RESULTS
Ten percent (n = 154) of patients had an AVF, 21% (n = 326) had an AVG, and 69% (n = 1083) had a CVC at dialysis initiation; those who were most likely to use an AVF were white and male. After statistical adjustment, patients with persistent AVF use reported greater physical activity and energy, better emotional and social well-being, fewer symptoms, less effect of dialysis and burden of kidney disease, and better sleep compared with patients with persistent CVC use, whereas measures such as cognitive and sexual function did not differ by access type.


CONCLUSIONS
Compared with persistent CVC use, early persistent AVF use is associated with the perception of improved health status and QOL among patients with ESRD. Future longitudinal studies may help to clarify further the association between QOL and vascular access.
Wasse
Haimanot
H
Department of Medicine, Renal Division, Emory University, Atlanta, GA 30322, USA. hwasse@emory.edu
Kutner
Nancy
N
Zhang
Rebecca
R
Huang
Yijian
Y
D000293:Adolescent; D000328:Adult; D000368:Aged; D002408:Catheters, Indwelling; D005260:Female; D006304:Health Status; D006801:Humans; D008297:Male; D008875:Middle Aged; D011788:Quality of Life; D006435:Renal Dialysis
Clin Nephrol. 2003 Apr;59(4):280-8
12708568
Semin Dial. 2003 May-Jun;16(3):263-5
12753689
Kidney Int Suppl. 2003 Nov;(87):S78-86
14531778
Am J Kidney Dis. 2003 Nov;42(5):1013-9
14582045
QJM. 2003 Dec;96(12):899-909
14631056
J Am Soc Nephrol. 2004 Feb;15(2):477-86
14747396
Semin Dial. 2004 Mar-Apr;17(2):109-14
15043611
Am J Kidney Dis. 2004 Jun;43(6):999-1007
15168379
Kidney Int. 2004 Jul;66(1):355-66
15200444
Electroencephalogr Clin Neurophysiol. 1980 May;48(5):583-94
6153966
ASAIO Trans. 1991 Jul-Sep;37(3):M456-7
1751235
Health Econ. 1993 Oct;2(3):217-27
8275167
ASAIO J. 2000 May-Jun;46(3):279-82
10826736
Am J Kidney Dis. 2001 Jan;37(1 Suppl 1):S137-81
11229969
Kidney Int. 2001 Jul;60(1):1-13
11422731
Kidney Int. 2001 Oct;60(4):1443-51
11576358
Kidney Int. 2002 Aug;62(2):620-6
12110026
Qual Life Res. 2002 Aug;11(5):437-47
12113391
Am J Kidney Dis. 2002 Dec;40(6):1202-10
12460039
Am J Kidney Dis. 2003 Feb;41(2):394-402
12552502
Am J Kidney Dis. 1995 Nov;26(5):751-6
7485127
Am J Kidney Dis. 1997 Oct;30(4 Suppl 3):S150-91
9339150
Am J Kidney Dis. 1998 Apr;31(4):593-601
9531174
Am J Nephrol. 1998;18(5):379-83
9730560
Infect Control Hosp Epidemiol. 1998 Sep;19(9):643-6
9778161
Adv Ren Replace Ther. 1999 Apr;6(2):141-8
10230881
Kidney Int. 2004 Dec;66(6):2429-36
15569336
Am J Kidney Dis. 2005 Feb;45(2):303-8
15685508
Nephrol Dial Transplant. 2005 Mar;20(3):571-7
15671074
Sleep Med. 2005 May;6(3):283-5
15854861
J Am Soc Nephrol. 2005 May;16(5):1449-55
15788468
J Am Soc Nephrol. 2005 Aug;16(8):2487-94
15975996
Kidney Int. 2006 May;69(9):1626-32
16672924
Semin Dial. 2006 May-Jun;19(3):210-6
16689972
Am J Kidney Dis. 2007 Feb;49(2):276-83
17261430
Health Qual Life Outcomes. 2003;1:68
14633280